Survival time and prognostic factors in canine leishmaniosis in a non-endemic country treated with a two-phase protocol including initial allopurinol monotherapy

Table 2 Summary of clinicopathological parameters

Parameter	n	Median	Range	Reference range used
Hematology
Hematocrit	46	0.34	0.10–0.58	0.42–0.61 L/L
Reticulocytes, corrected^a	26	0.5	0.1–7.5	< 1.5%
Leukocytes	46	7.0	2.0–31.9	4.5–14.6 × 10⁹/L
Segments/neutrophils	45	4.4	0.2–27.4	2.9–11.0 × 10⁹/L
Bands	45	0	0–2.1	0.0–0.3 × 10⁹/L
Lymphocytes	45	1.6	0.1–4.2	0.8–4.7 × 10⁹/L
Monocytes	45	0.4	0–2.7	0.0–0.9 × 10⁹/L
Eosinophils	45	0.2	0–1	0.0–1.6 × 10⁹/L
Basophils	45	0	0–0.2	0.0–0.1 × 10⁹/L
Thrombocytes^b	46	195	33–572	144–603 × 10⁹/L
Biochemistry
Urea	34	5.2	2.4–12	3.0–12.5 mmol/L
Creatinine^c	41	68.8	17.4–470.1	50–129 μmol/L
Total protein	47	75	44–136	55–72 g/L
Albumin	47	25	7–39	26–37 g/L
Alpha 1	44	3	1–8	5–10 g/L
Alpha 2	44	10	5–16	4–13 g/L
Beta 1	44	4	2–9	3–10 g/L
Beta 2	44	10.5	3–54	4–10 g/L
Gamma	44	22.5	5–79	3–9 g/L
Urine analysis
Urine specific gravity	33	1.027	1.008–1.051
UPC	35	0.9	0.06–14.14	< 1.0

n Number of dogs for which the data were available, UPC urine protein to creatinine ratio
^aReticulocyte percentages were corrected for hematocrit as follows: reticulocyte × (hematocrit/0.50)
^bValues < 80 × 10⁹/L were considered to indicate thrombocytopenia
^cAll creatinine values were corrected for body weight; the reference range is a standard reference range

ISSN: 1756-3305